Possible Effect of Intravenous Immunoglobulin Therapy for Unexplained Secondary Recurrent Miscarriage

F. A. Saad; M. A. M. Shahata; O. B. Christiansen

doi:10.5339/qmj.2003.2.9

ISSN: 0253-8253
E-ISSN: 2227-0426

oa Possible Effect of Intravenous Immunoglobulin Therapy for Unexplained Secondary Recurrent Miscarriage

Authors: F. A. Saad¹, M. A. M. Shahata¹, O. B. Christiansen²
View Affiliations Hide Affiliations

Affiliations: ¹ ^*Recurrent Pregnancy Loss Clinic, Department of Obstetrics and Gynecology, Women's Hospital, Hamad Medical Corporation, Doha, Qatar ² ^**Fertility Clinic 4071, Rigshospitalet, Copenhagen, Denmark
Source: Qatar Medical Journal, Volume 2003, Issue 2, Dec 2003,
DOI: https://doi.org/10.5339/qmj.2003.2.9
- Published online: 01 Dec 2003

Abstract

Objective. To review the role of intravenous immunoglobulin (IVIG) in the prevention of recurrent miscarriage (RM). Methods. In a prospective controlled clinical tria], 40 women with a history of unexplained. RMwere treated with IVIG, according to a specific protocol and compared to another 40 women who had the same condition and treated with tender loving care and vitamins only. The birth of a child of more than 28 weeks gestation was considered a successful outcome.

Results. The overall success rate was 60% in the IVIG group compared with 52.6% in the control group (P = 0.65). The success rates for women with primary RM were 56.3% for IVIG group and 68.8% for the control group (P = 0.72). The success rates for women with secondary RM were 62.5% and 41.7% respectively (P = 0.25). None of the previous results is statistically significant.

Conclusion. Women with unexplained RM in general have a good prognosis. IVIG did not improve the prognosis significantly in the total group of patients compared with controls. However; further investigations are needed to explore whether the 21 % therapeutic benefit of IVIG in patients with secondary RM indicates that the treatment is efficient in this subset of patients.

Article metrics loading...

/content/journals/10.5339/qmj.2003.2.9

2003-12-01

2019-08-18

From This Site

/content/journals/10.5339/qmj.2003.2.9

dcterms_title,dcterms_subject,pub_keyword

10

5

Full text loading...

References

1. Carp HJA., , Toder V., , Gazit E., , Ahiron A., , Torchinski S., , Mashiash S., , Shoenfeld Y. . Further experience with intravenous immunoglobulin in women with recurrent miscarriage and a poor prognosis. . American Journal of Reproductive Immunology . 2001; ;46: : 268– – 273 .
[Google Scholar]
2. Christiansen OB., , Mathiesen 0., , Lauritsen JG., , Grunnet N. . Intravenous immunoglobulin treatment of women with multiple miscarriages. . Human Reproduction . 1992; ;7: : 718– – 722 .
[Google Scholar]
3. Christiansen OB., , Mathiesen 0., , Husth M., , Rasmussen KL., , Ingerslev HJ., , Lauritsen JG., , Grunnet N. . Placebocontrolled trial of treatment of unexplained secondary recurrent spontaneous abortions and recurrent late spontaneous abortions with i.v. immunoglobulin. . Human Reproduction . 1995; ;10: : 2690– – 2695 .
[Google Scholar]
4. Christiansen OB., , Klipatrick DC., , Souter V., , Warming K., , Thiel S., , Jensenius JC. . Mannan-binding lectin deficiency is associated with unexplained recurrent miscarriage. . Scandinavian Journal of Immunology . 1998; ;49: : 193– – 196 .
[Google Scholar]
5. Christiansen OB., , Pedersen B., , Rosgaard A., , Husth M. . A randomized, double-blind, placebo-controlled trial of intravenous immunoglobulin in the prevention of recurrent miscarriage: evidence for a therapeutic effect in women with secondary recurrent miscarriage. . Human Reproduction . 2002; ;17: : 809– – 816 .
[Google Scholar]
6. Clifford K., , Rai R., , Watson H., , Regan L. . An informative protocol for the investigation of recurrent miscarriage: Preliminary experience of500 consecutive cases. . Human Reproduction . 1994; ;9: : 1328– – 1332 .
[Google Scholar]
7. Coulam CB., , Krysa L., , Stem JJ., , Bustillo M. . Intravenous immunoglobulin for treatment of recurrent pregnancy loss. . American Journal of Reproductive Immunology . 1995; ;34: : 333– – 337 .
[Google Scholar]
8. Daya S., , Gunby J., , Clark DA. . Intravenous immunoglobulin therapy for recurrent spontaneous abortion: A metaanalysis. . American Journal of Reproductive Immunology . 1998; ;39: 2 : 69– – 76 .
[Google Scholar]
9. German RSA/IVIG group . Intravenous immunoglobulin in the prevention of recurrent miscarriage. . British Journal of Obstetrics and Gynaecology . 1994; ;101: : 1072– – 1077 .
[Google Scholar]
10. Heine O., , Mueller-Eckhardt G. . Intravenous immunoglobulin in recurrent abortion. . Clinical and Experimental Immunology . 1994; ;97: : 39– – 42 .
[Google Scholar]
11. Jablonowska B., , Selbing A., , Palfi M., , Emerudh J., , Kjellberg S., , Lindton B. . Prevention of recurrent spontaneous abortion by intravenous immunoglobulin: A double-blind placebocontrolled study. . Human Reproduction . 1999; ;14: : 838– – 841 .
[Google Scholar]
12. Mueller-Eckhardt G., , Heine O., , Neppert J., , Kunzel W., , Mueller-Eckhardt C. . Prevention of recurrent spontaneous abortion by intravenous immunoglobulin. . Vox Sang. 1989; ;56: : 151– – 154 .
[Google Scholar]
13. Mueller-Eckhardt G., , Heine O., , Polten BIVIG. . to prevent recurrent spontaneous abortion. . Lancet . 1991; ;337: : 425– – 426 .
[Google Scholar]
14. Perino A., , Vassiliadis A., , Vucetich A., , Colacurci N., , Menato G., , Cignitti M., , Semprini AE. . Short-term therapy for recurrent abortion using intravenous immunoglobulins: Results of a double-blind placebo-controlled Italian study. . Human Reproduction . 1997; ;12: : 2388– – 2392 .
[Google Scholar]
15. Pfeiffer KA., , Fimmers R., , Engels G., , van der Yen H., , Van der Yen K. . The HLA-G genotype is potentially associated with idiopathic recurrent spontaneous abortion. . Mol. Hum. Reprod. 2001; ;7: : 373– – 378 .
[Google Scholar]
16. Piccinni MP., , Beloni L., , Livi C., , Maggi E., , Scarselli G., , Romagnani S. . Defective production on both leukemia inhibitory factor and type-2 T-helper cytokines by decidual T cells in unexplained recurrent abortions. . Nat Med . 1998; ; : 1020– – 1024 .
[Google Scholar]
17. Ronda N., , Hurez V., , Kazatchkine MD. . Intravenous immunoglobulin therapy for autoimmune and systemic inflammatory diseases. . Vox Sang . 1993; ;64: : 65– – 72 .
[Google Scholar]
18. Sacks G., , Sargent I., , Redman C. . An innate view of human pregnancy. . Immunology Today . 1999; ;20: : 114– – 118 .
[Google Scholar]
19. Stephenson MD., , Dreher K., , Houlihan E., , Wu V. . Prevention of unexplained recurrent spontaneous abortion using intravenous immunoglobulin: A prospective, randomized, double-blinded, placebo-controlled trial. . American Journal of Reproductive Immunology . 1998; ;39: : 82– – 88 .
[Google Scholar]
20. Thornton CA., , Ballow M. . Safety of intravenous immunoglobulin. . Achieve of Neurology . 1993; ;50: : 135– – 136 .
[Google Scholar]

http://instance.metastore.ingenta.com/content/journals/10.5339/qmj.2003.2.9

Article Type: Research Article

oa Possible Effect of Intravenous Immunoglobulin Therapy for Unexplained Secondary Recurrent Miscarriage

Abstract

From This Site

Most Read This Month